1.655

2.65% -0.045

Entera Bio Ltd (ENTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.70

Aprire:

$1.69

Volume 24 ore:

73,613

Relative Volume:

0.08

Capitalizzazione di mercato:

$81.58M

Reddito:

$42,000

Utile/perdita netta:

$-12.38M

Rapporto P/E:

-6.2832

EPS:

-0.2634

Flusso di cassa netto:

$-9.61M

1 W Prestazione:

-0.30%

1M Prestazione:

+41.45%

6M Prestazione:

+3.44%

1 anno Prestazione:

-10.05%

Intervallo 1D:

$1.61

$1.71

Intervallo di 1 settimana:

$1.585

$1.86

Portata 52W:

$0.91

$3.22

Entera Bio Ltd Stock (ENTX) Company Profile

Nome

Entera Bio Ltd

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

972-2-532-7151

Indirizzo

KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-14

Ultimi documenti SEC

ENTX's Discussions on Twitter

Compare ENTX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ENTX Entera Bio Ltd	1.655	81.58M	42,000	-12.38M	-9.61M	-0.2634
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-03-22	Iniziato	Aegis Capital	Buy

Entera Bio Ltd Borsa (ENTX) Ultime notizie

Jul 08, 2026

America's Osteoporosis Crisis and the Oral Peptide Player You Should Watch (NASDAQ: ENTX) - Benzinga

Jul 08, 2026

Jun 29, 2026

Take the Zacks Approach to Beat the Market: Dell, Caterpillar, Amkor in Focus - TradingView

Jun 29, 2026

Jun 27, 2026

Price to earnings forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView

Jun 27, 2026

Price to earnings forward of Entera Bio Ltd. – FWB:5DT - TradingView

Jun 27, 2026

Enterprise value to revenue forward of Entera Bio Ltd. – NASDAQ:ENTX - TradingView

Jun 27, 2026

Enterprise value to revenue forward of Entera Bio Ltd. – LSX:A2JQXP - TradingView

Jun 26, 2026

Jun 25, 2026

Entera Bio Ltd. Actuals & Estimates (HAM:5DT) - TradingView

Jun 25, 2026

ENTX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

5DT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback - Investing.com UK

Jun 24, 2026

H.C. Wainwright reiterates Entera Bio stock rating on FDA feedback By Investing.com - Investing.com Australia

Jun 24, 2026

H.C. Wainwright Maintains Entera Bio(ENTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo

Jun 24, 2026

Jun 23, 2026

Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market - GlobeNewswire Inc.

Jun 23, 2026

3 Promising Penny Stocks With Market Caps Under $600M - simplywall.st

Jun 23, 2026

Jun 22, 2026

ENTX Stock Pops As Entera Bio Showcases ENDO 2026 Pipeline - timothysykes.com

Jun 22, 2026

ENTX stock on track for best day in over 5 years — what’s driving the rally? - MSN

Jun 22, 2026

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally? - Yahoo Finance

Jun 22, 2026

FDA backs Entera Bio’s 750-patient osteoporosis trial for EB613 - Stock Titan

Jun 22, 2026

With Positive FDA Feedback on Phase 3, Entera Bio Just Got the Answer the Market Was Waiting For - TipRanks

Jun 22, 2026

Entera Bio Advances Oral Osteoporosis Drug EB613 With Positive FDA Feedback - marketscreener.com

Jun 22, 2026

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis - The Manila Times

Jun 22, 2026

Entera Bio Receives Positive FDA Feedback on 12-Month - GlobeNewswire

Jun 22, 2026

Jun 18, 2026